ArticlePloS one2025
Association of renal hyperfiltration with incidence of dyslipidemia: a nationwide retrospective longitudinal cohort study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Higher Small Dense LDL Cholesterol to LDL Cholesterol Ratio is Associated with Glomerular Hyperfiltration in Adults without Diabetes.Journal of atherosclerosis and thrombosis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndividuals with chronic kidney disease (CKD) are often diagnosed with dyslipidemia, contributing to their cardiovascular risk. However, the relationship between renal hyperfiltration (RHF) and dyslipidemia remains unclear. Here, we aimed to examine the association between RHF and incidence of dyslipidemia.
methodsWe examined the data of 2,780,874 participants who underwent health examinations between 2010 and 2011 from the Korean NHIS-HEALS database. Renal function was assessed using estimated glomerular filtration rate (eGFR) levels that were calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. The incidence of dyslipidemia was defined as the outcome. Dyslipidemia was characterized by meeting the following criteria: having at least one claim of International Classification of Diseases (ICD)-10 code (E78) with an anti-dyslipidemia agent prescription, claims of ICD-10 code (E78) occurring more than twice, a total cholesterol level ≥ 240 mg/dL, low-density lipoprotein cholesterol ≥ 160 mg/dL, triglycerides ≥ 200 mg/dL, or high-density lipoprotein cholesterol < 40 mg/dL. RHF was defined as having an eGFR > 120 mL/min ∙ 1.73 m2 defined by the eGFR range or being in the 10th decile of whole eGFR level.
resultsOver a median follow-up of 9.56 years, 2,243,502 participants with dyslipidemia were identified. The mean age of participants was 47.35 ± 13.96 years. In the multivariable Cox regression analysis, eGFR > 120 mL/min ∙ 1.73 m2 was associated with a decreased risk of dyslipidemia (HR: 0.35; 95% CI [0.34-0.36]). Furthermore, compared to the fifth decile, tenth (≥ 114.21) (HR: 0.47, 95% CI (0.46-0.48) eGFR deciles were significantly associated with a reduced incidence of dyslipidemia.
conclusionsThe general population with RHF may have a lower risk of incidence of dyslipidemia. The identified inverse association between RHF and dyslipidemia underscores its significance in risk stratification and preventive interventions in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.